fine line chemotherapy
Showing 26 - 50 of >10,000
Malignant Pleural Mesothelioma Trial in Cairo (Gemcitabine, supportive care)
Not yet recruiting
- Malignant Pleural Mesothelioma
- Gemcitabine
- supportive care
-
Cairo, EgyptAin Shams University Hospital
Dec 20, 2022
Gynecologic Cancer Trial (Experimental product - Fortifit® Powder, Standard of care)
Not yet recruiting
- Gynecologic Cancer
- Experimental product - Fortifit® Powder
- Standard of care
- (no location specified)
Oct 14, 2023
Persistent, Recurrent, or Metastatic Cervical Cancer Trial in Shanghai (GLS-010, Placebo, paclitaxel)
Not yet recruiting
- Persistent, Recurrent, or Metastatic Cervical Cancer
- GLS-010
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Hospital
Apr 4, 2023
Recurrent Liver Cancer After Liver Transplantation Trial (Hepatic arterial infusion chemo + Atezolizumab and bevacizumab)
Not yet recruiting
- Recurrent Liver Cancer After Liver Transplantation
- Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
- (no location specified)
Apr 17, 2023
Recurrent or Progressive Glioblastoma Trial in Detroit (Bevacizumab, Bevacizumab with chemo, Fractionated radiosurgery)
Completed
- Recurrent or Progressive Glioblastoma
- Bevacizumab
- +2 more
-
Detroit, MichiganHenry Ford Health System
Jan 30, 2023
NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))
Withdrawn
- NSCLC Stage IV
- combination regimen tremelimumab /durvalumab
- platinum-based chemotherapy (SoC)
-
Gauting, GermanyAsklepios Fachkliniken München-Gauting
Sep 26, 2022
Triple Negative Breast Cancer Trial (Ociperlimab, Tislelizumab, Paclitaxel)
Not yet recruiting
- Triple Negative Breast Cancer
- Ociperlimab
- +7 more
- (no location specified)
Mar 30, 2023
Pancreatic Tumors Trial in Shanghai (Utidelone injection in combination with gemcitabine)
Recruiting
- Pancreatic Neoplasms
- Utidelone injection in combination with gemcitabine
-
Shanghai, Shanghai, ChinaShanghai First People's Hospital
Mar 21, 2023
Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)
Not yet recruiting
- Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
- SG001 injection
- +5 more
- (no location specified)
Jan 27, 2023
Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,
Not yet recruiting
- Advanced Lung Squamous Cell Carcinoma
- low-dose radiation therapy and stereotactic body radiation therapy
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Nov 13, 2023
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Trial in Beijing (Niraparib)
Recruiting
- Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
-
Beijing, Beijing, ChinaPeking University Cancer Hospital
Nov 15, 2023
Acute Myeloid Leukemia, MDS Trial (idarubicin, Cytarabine)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- (no location specified)
Sep 18, 2023
NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Ociperlimab
- +8 more
- (no location specified)
Mar 17, 2023
Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy Trial in Jinan (TQB2450 Injection +
Recruiting
- Limited Stage Small Cell Lung Cancer
- Not Progressed After First-line Chemoradiotherapy
- TQB2450 Injection + Anlotinib Hydrochloride Capsules
-
Jinan, Shandong, ChinaCancer Hospital Affiliated to Shandong First Medical University
Jul 5, 2023
Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)
Not yet recruiting
- Cervical Cancer
- TQB2868 injection
- +4 more
-
Chongqing, Chongqing, China
- +1 more
Aug 17, 2023
Colorectal Cancer Trial in Shanghai (VIC, Bevacizumab Plus Chemotherapy)
Recruiting
- Colorectal Cancer
- VIC
- Bevacizumab Plus Chemotherapy
-
Shanghai, ChinaDepartment of General Surgery, Zhongshan Hospital, Fudan Univers
Sep 14, 2022
Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer Trial (Durvalumab, Monalizumab, Carboplatin or Cisplatin)
Not yet recruiting
- Small Cell Lung Cancer
- +2 more
- Durvalumab
- +3 more
- (no location specified)
Jun 5, 2023
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint
Active, not recruiting
- Recurrent Nasopharyngeal Carcinoma
- +2 more
- PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
-
Guangzhou, Guangdong, ChinaYanqun Xiang
Sep 5, 2022
Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of
Not yet recruiting
- Triple Negative Breast Cancer
- +2 more
- Everolimus
- Investigator's Choice of Chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 25, 2023
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
Unresectable Locally Advanced or Metastatic Pancreatic Cancer Trial in Shanghai (surufatinib, KN046, gemcitabine)
Not yet recruiting
- Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- surufatinib
- +3 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital
Apr 16, 2023
Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer Trial (TST001, CapOx or mFOLFOX6 and NIVO or (Substudy)
Not yet recruiting
- Gastric Cancer
- +2 more
- TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- (no location specified)
Oct 16, 2023